Thiazolidinedione‐Pyrimidine Hybrid as Potential Antidiabetic Agents and Their Cardioprotective Effect

Fuente: Wiley Open Access
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Shaista Amin, Faizul Azam, Sayima Nabi, Mohammad Ahmed Khan, Anam Abdullah, M. Shaquiquzzaman, Ashif Iqubal, Mymoona Akhter, Sharba Tasneem, Suruchi Khanna, Prawez Alam, M. Mumtaz Alam
Format: Artículo Open Access
Veröffentlicht: Wiley 2025
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867003278246543360
author Shaista Amin
Faizul Azam
Sayima Nabi
Mohammad Ahmed Khan
Anam Abdullah
M. Shaquiquzzaman
Ashif Iqubal
Mymoona Akhter
Sharba Tasneem
Suruchi Khanna
Prawez Alam
M. Mumtaz Alam
author_facet Shaista Amin
Faizul Azam
Sayima Nabi
Mohammad Ahmed Khan
Anam Abdullah
M. Shaquiquzzaman
Ashif Iqubal
Mymoona Akhter
Sharba Tasneem
Suruchi Khanna
Prawez Alam
M. Mumtaz Alam
Shaista Amin
Faizul Azam
Sayima Nabi
Mohammad Ahmed Khan
Anam Abdullah
M. Shaquiquzzaman
Ashif Iqubal
Mymoona Akhter
Sharba Tasneem
Suruchi Khanna
Prawez Alam
M. Mumtaz Alam
collection Wiley Open Access
contents Thiazolidinedione‐Pyrimidine Hybrid as Potential Antidiabetic Agents and Their Cardioprotective Effect Shaista Amin Faizul Azam Sayima Nabi Mohammad Ahmed Khan Anam Abdullah M. Shaquiquzzaman Ashif Iqubal Mymoona Akhter Sharba Tasneem Suruchi Khanna Prawez Alam M. Mumtaz Alam Journal of Heterocyclic Chemistry ABSTRACTThe leading cause of death in diabetic patients is diabetic cardiomyopathy (DCM). Despite the availability of anti‐diabetic medications which effectively curb the hyperglycemia, the drug molecule which alleviates the severity of DCM along with the maintenance of a normoglycemic profile of diabetic patients is still unexplored. In this study, a series of thiazolidinedione‐pyrimidine hybrid compounds were synthesized, and their anti‐diabetic potential was explored in STZ‐NA induced diabetic Wistar rats. The role of these compounds in DCM was also evaluated. The most potent compound, PT‐5, showed significant reduction in blood glucose levels (from 129 to 115 mg/dL in 2 h) in comparison to the standard drug Pioglitazone (135–117 in 2 h). The biochemical estimations of AST, ALT, ALP, Troponin T, Cκ‐MB, CRP, and LDH levels illustrated that the levels appreciably came back to normal in the PT‐1, PT‐5, and PT‐13 treatment groups. The cardioprotective role was further validated by cardiac tropism indices and levels of antioxidants in cardiac tissue. The biochemical assessments were further validated through histopathological studies. This research indicates that these derivatives hold promise for the development of new potential antidiabetic agents. 10.1002/jhet.70021 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/jhet.70021
format Artículo Open Access
id wiley_oa_10_1002_jhet_70021
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Thiazolidinedione‐Pyrimidine Hybrid as Potential Antidiabetic Agents and Their Cardioprotective Effect
Shaista Amin
Faizul Azam
Sayima Nabi
Mohammad Ahmed Khan
Anam Abdullah
M. Shaquiquzzaman
Ashif Iqubal
Mymoona Akhter
Sharba Tasneem
Suruchi Khanna
Prawez Alam
M. Mumtaz Alam
Journal of Heterocyclic Chemistry
Thiazolidinedione‐Pyrimidine Hybrid as Potential Antidiabetic Agents and Their Cardioprotective Effect Shaista Amin Faizul Azam Sayima Nabi Mohammad Ahmed Khan Anam Abdullah M. Shaquiquzzaman Ashif Iqubal Mymoona Akhter Sharba Tasneem Suruchi Khanna Prawez Alam M. Mumtaz Alam Journal of Heterocyclic Chemistry ABSTRACTThe leading cause of death in diabetic patients is diabetic cardiomyopathy (DCM). Despite the availability of anti‐diabetic medications which effectively curb the hyperglycemia, the drug molecule which alleviates the severity of DCM along with the maintenance of a normoglycemic profile of diabetic patients is still unexplored. In this study, a series of thiazolidinedione‐pyrimidine hybrid compounds were synthesized, and their anti‐diabetic potential was explored in STZ‐NA induced diabetic Wistar rats. The role of these compounds in DCM was also evaluated. The most potent compound, PT‐5, showed significant reduction in blood glucose levels (from 129 to 115 mg/dL in 2 h) in comparison to the standard drug Pioglitazone (135–117 in 2 h). The biochemical estimations of AST, ALT, ALP, Troponin T, Cκ‐MB, CRP, and LDH levels illustrated that the levels appreciably came back to normal in the PT‐1, PT‐5, and PT‐13 treatment groups. The cardioprotective role was further validated by cardiac tropism indices and levels of antioxidants in cardiac tissue. The biochemical assessments were further validated through histopathological studies. This research indicates that these derivatives hold promise for the development of new potential antidiabetic agents. 10.1002/jhet.70021 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Thiazolidinedione‐Pyrimidine Hybrid as Potential Antidiabetic Agents and Their Cardioprotective Effect
topic Journal of Heterocyclic Chemistry
url https://onlinelibrary.wiley.com/doi/10.1002/jhet.70021